Topic: Cardiovascular disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the trial 2. Male or female, aged 18 years or above 3. Diagnosed with heart failure, defined as presence of typical symptoms (e.g. breathlessness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) resulting from an abnormality of cardiac structure or function 4. Potential to benefit from home monitoring and management defined as: 4.1. Self-assessed NYHA class II to IV; or 4.2. BNP >100 pg/L or NT-pro-BNP >360 pg/L in the last 30 days (excluding in-hospital measures) AND either 4.3. Not on optimal therapy (in view of the Investigator), or 4.4. Probability of death within one year >10% (MAGGIC integer score 20 or more) 4.5. At least one hospital admission related to heart failure in the previous 12 months
Exclusion criteria
Exclusion criteria: 1. No reliable 3G mobile or Wi-Fi network connectivity at home 2. Unable to read or speak English 3. Any other significant disease, including critical unstable or end-stage heart failure, which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant?s ability to participate in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimal medical therapy is defined as treatment consistent with the NICE guidelines for management of patients with chronic heart failure and will be measured as a composite opportunity score | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom